User settings
+7 (701) 759 90 19 Лента
USD 386.34 EUR 427.25
RUB 5.88 CNY 54.57
News

FDA approves new drug for deadly tuberculosis

15 August 2019 15:16 42
Share in:
FDA approves new drug for deadly tuberculosis

WASHINGTON. KAZINFORM The U.S. Food and Drug Administration (FDA) approved on Wednesday a new drug for the treatment of a deadly type of treatment-resistant tuberculosis, one of the world's leading infectious causes of death.

Related news
Low levels of vitamin D in elementary school could spell trouble in adolescence: study Childhood autism morbidity grew 12% in Kazakhstan Genes linked to Alzheimer's risk, resilience identified

The tablets called Pretomanid is approved in combination with bedaquiline and linezolid for treating a limited and specific population of adult patients with extensively drug resistant, treatment-intolerant or nonresponsive multidrug resistant tuberculosis of the lung, according to FDA, Xinhua reports.

In 2017, a total of 10 million people fell ill with tuberculosis, and 1.6 million died from the disease, according to the World Health Organization (WHO).

In 2016, there were an estimated 490,000 new cases of multidrug-resistant tuberculosis worldwide, with a smaller portion of cases of highly-lethal extensively drug-resistant tuberculosis, according to WHO.

The new drug's safety and effectiveness, taken orally in combination with bedaquiline and linezolid, was primarily demonstrated in a study of 109 patients with extensively drug-resistant pulmonary tuberculosis. Of the 107 patients who were evaluated 6 months after the end of therapy, 95 (89 percent) were deemed as successes, significantly exceeding the historical success rates for treatment of extensively drug resistant tuberculosis, according to FDA.

The three-drug regimen with a 6-month treatment also simplifies and shortens the therapy for extensively drug resistant tuberculosis that previously might take between six and eight drugs for two years or longer.

It is the third FDA-approved anti-tuberculosis drug in more than 40 years.


Keywords: Healthcare,
Share in:
+7
Send
Employees online
Editor
Nurmaganbetova Zhanna
Nurmaganbetova Zhanna
954-048
Editor
Kudrenok Tatyana
Kudrenok Tatyana
954-048
Editor
Temirgaliyeva Arailym
Temirgaliyeva Arailym
954-048

Archive